A Study to Compare LBVD to Eupenta and Imovax Polio in Healthy Adults

Launched by LG CHEM · Jun 30, 2017

Keywords

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Healthy adults between 19 and 55 years of age at the time of Visit 1 (Screening)
• • 2. Persons who or whose legal representatives have voluntarily signed an informed consent after receiving explanation about the objectives, methods, effects, etc. of the clinical study
• • 3. Persons who are surgically sterile, postmenopausal women, or agree to use contraceptive measures
• Exclusion Criteria:
• • 1. Persons who have an experience of participation in another interventional clinical study within 3 months prior to Visit 1 (Screening)
• • 2. Persons who have a record of vaccination with the tetanus toxoid (TT)/tetanus diphtheria (Td)/tetanus diphtheria pertussis (Tdap) vaccine or other vaccines containing tetanus-diphtheria for adults or who are suspected to have been vaccinated with either of them within 5 years prior to Visit 1 (Screening)
• • 3. Persons who were vaccinated within 4 weeks prior to Visit 1 (Screening) or who are scheduled to be vaccinated with the vaccines other than the study vaccine during the study period
• • 4. Persons with a history of diphtheria, tetanus, pertussis, hepatitis B virus, polio virus, or the invasive diseases caused by Haemophilus influenzae type b